Hiroyuki Kagechika

Prof. Dr. Hiroyuki Kagechika

Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TYT. Yamauchi
T. Yamauchi
JKJ. Kamon
J. Kamon
HWH. Waki
H. Waki
YTY. Terauchi
Y. Terauchi
NKN. Kubota
N. Kubota
TKT. Kadowaki
T. Kadowaki

1 October 2004 in Immunity
Verified
Journal Article
Closed access
MIMakoto Iwata
Makoto Iwata
AHAsami Hirakiyama
Asami Hirakiyama
YEYuko Eshima
Yuko Eshima
HKHiroyuki Kagechika
Hiroyuki Kagechika
CKChieko Kato
Chieko Kato
SSSi-Young Song
Si-Young Song

5 December 2010 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JHJeffrey K Huang
Jeffrey K Huang
AJAndrew A Jarjour
Andrew A Jarjour
BOBrahim Nait Oumesmar
Brahim Nait Oumesmar
CKChristophe Kerninon
Christophe Kerninon
AWAnna Williams
Anna Williams
RFRobin J M Franklin
Robin J M Franklin

8 July 2002 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TSTakayuki Shindo
Takayuki Shindo
IMIchiro Manabe
Ichiro Manabe
YFYasushi Fukushima
Yasushi Fukushima
KTKazuyuki Tobe
Kazuyuki Tobe
KAKenichi Aizawa
Kenichi Aizawa
RNRyozo Nagai
Ryozo Nagai

1 August 2003 in International Immunology
Verified
Journal Article
Open access
PDF file
MIMakoto Iwata
Makoto Iwata
YEYuko Eshima
Yuko Eshima
HKHiroyuki Kagechika
Hiroyuki Kagechika
The vitamin A metabolite, retinoic acid (RA), affects Th1 and Th2 development. The effect is partly exerted through the modulation of antigen‐presenting cell functions, but it remains unclear whether RA directly exerts its effect on T cells to influence Th1/Th2 development. To clarify this problem, we used two experimental systems with isolated T cells in vitro. In one system, isolated CD4+CD8+ thymocytes differentiated into Th1 and Th2 by two transient stimulations with defined combinations of ionomycin and phorbol myristate acetate followed by treatment with IL‐2 and IL‐4 and/or IL‐12. In the second system, functional differentiation was induced in purified naive CD4 T cells from DO‐11.10 TCR‐transgenic and RAG‐2‐deficient mice with cytokines and antibodies to CD3 and CD28. In both systems, all‐trans‐RA at ≥1 nM concentrations suppressed Th1 development, but enhanced Th2 development. 9‐cis‐RA elicited similar effects. The optimal enhancement of Th2 development in the second system, however, was achieved with a delayed addition of RA. The presence of RA during the initial stimulation period often suppressed Th2 development. The RA receptor (RAR) antagonists, LE540 and LE135, but not the retinoic X receptor (RXR) antagonist, PA452, inhibited the effect of RA on Th1/Th2 development. Accordingly, the RAR agonists, Am80 and Tp80, but not the RXR agonists, HX600 and TZ335, mimicked the effect of RA. The RXR agonists enhanced the effect of the RAR agonists only slightly, if at all. These results indicate that, via RAR, RA directly suppresses Th1 development and directly enhances Th2 development with its timely addition.

1 November 1988 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HKHiroyuki Kagechika
Hiroyuki Kagechika
EKEmiko Kawachi
Emiko Kawachi
YHYuichi Hashimoto
Yuichi Hashimoto
KSKoichi Shudo
Koichi Shudo
THToshiyuki Himi
Toshiyuki Himi